TCON vs. FNCH, KRBP, ALBT, ELOX, PALI, GMDAQ, GMDA, FRTX, CELZ, and TTNP
Should you be buying TRACON Pharmaceuticals stock or one of its competitors? The main competitors of TRACON Pharmaceuticals include Finch Therapeutics Group (FNCH), Kiromic BioPharma (KRBP), Avalon GloboCare (ALBT), Eloxx Pharmaceuticals (ELOX), Palisade Bio (PALI), Gamida Cell (GMDAQ), Gamida Cell (GMDA), Fresh Tracks Therapeutics (FRTX), Creative Medical Technology (CELZ), and Titan Pharmaceuticals (TTNP). These companies are all part of the "biological products, except diagnostic" industry.
TRACON Pharmaceuticals (NASDAQ:TCON) and Finch Therapeutics Group (NASDAQ:FNCH) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, earnings, community ranking, media sentiment, analyst recommendations, risk, dividends, institutional ownership and profitability.
TRACON Pharmaceuticals presently has a consensus target price of $60.00, suggesting a potential upside of 3,362.40%. Given TRACON Pharmaceuticals' higher probable upside, equities analysts plainly believe TRACON Pharmaceuticals is more favorable than Finch Therapeutics Group.
TRACON Pharmaceuticals received 255 more outperform votes than Finch Therapeutics Group when rated by MarketBeat users. Likewise, 58.50% of users gave TRACON Pharmaceuticals an outperform vote while only 52.63% of users gave Finch Therapeutics Group an outperform vote.
TRACON Pharmaceuticals has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Finch Therapeutics Group has a beta of 0.46, suggesting that its share price is 54% less volatile than the S&P 500.
In the previous week, TRACON Pharmaceuticals had 2 more articles in the media than Finch Therapeutics Group. MarketBeat recorded 2 mentions for TRACON Pharmaceuticals and 0 mentions for Finch Therapeutics Group. TRACON Pharmaceuticals' average media sentiment score of 0.00 equaled Finch Therapeutics Group'saverage media sentiment score.
TRACON Pharmaceuticals' return on equity of -10.25% beat Finch Therapeutics Group's return on equity.
11.6% of TRACON Pharmaceuticals shares are owned by institutional investors. Comparatively, 21.8% of Finch Therapeutics Group shares are owned by institutional investors. 5.3% of TRACON Pharmaceuticals shares are owned by insiders. Comparatively, 44.9% of Finch Therapeutics Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
TRACON Pharmaceuticals has higher revenue and earnings than Finch Therapeutics Group. TRACON Pharmaceuticals is trading at a lower price-to-earnings ratio than Finch Therapeutics Group, indicating that it is currently the more affordable of the two stocks.
Summary
TRACON Pharmaceuticals beats Finch Therapeutics Group on 11 of the 15 factors compared between the two stocks.
Get TRACON Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for TCON and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TCON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
TRACON Pharmaceuticals Competitors List
Related Companies and Tools
